Apollo’s $145m financing will help advance its 15-plus candidate portfolio into clinical development. With Patient Square leading the round, its expertise with BridgeBio and co. will help guide Apollo’s evolution.

NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.

Fortress Biotech’s subsidiary will add the lentiviral gene therapy now in pair of Phase I/II trials to its pipeline. RXi partners with Karolinska to advance its self-delivering RNAi technology, while Avalon enlists Weill Cornell to enhance its CAR-T capabilities.

While Mustang was acquiring CAR-T intellectual property from Harvard and Juno licensed gamma-secretase inhibitor IP from OncoTracker and Fred Hutchinson for use with its CAR-Ts, Ocugen and Tamid licensed gene therapy research for ophthalmic uses.